Clinical trials: Non-Small Cell Lung Cancer (NSCLC), Stage I-IIIA
Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study
This phase I/II trial studies the side effects of sapanisertib and nivolumab and to see how well they work in treating patients with stage I-IV non-small cell lung cancer whose disease got worse on previous PD-1/PD-L1 inhibitor…
- Conditions
- Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
- Trial name
- NCT05022394
- Testing
- Nivolumab, Sapanisertib
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma of the Lung, Recurrent Non-small Cell Lung Cancer
Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer
This pilot clinical trial studies low-dose acetylsalicylic acid in treating patients with stage I-III non-small cell lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Recurrent Non-small Cell Lung Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer
- Trial name
- NCT01707823
- Testing
- acetylsalicylic acid, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lung Cancer, Non-Small Cell
Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery
The purpose of this clinical study is to assess the safety and immunogenicity of the immunotherapeutic product GSK 2302032A when given to Non-Small Cell Lung Cancer (NSCLC) patients, after tumor removal by surgery.
- Trial name
- NCT01159964
- Testing
- Immunotherapeutic GSK2302032A, different formulations
- Where
- 37 sites in United States, France and 4 more
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Lung Cancer, Surgery
Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.
This phase II trial studies how well intra-tumor injection of double checkpoint inhibitors work when given alone and in combination with chemotherapy or/and bevacizumab in treating patients with previously untreated stage I-IIIA…
- Conditions
- Lung Cancer, Surgery, Non-small Cell Lung Cancer
- Trial name
- NCT06492421
- Testing
- ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II
Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC)
In pre-clinical study, we found that serum thioredoxin reductase activity harbours huge difference after any kind of treatments, so we hypothesis that serum activity of thioredoxin reductase may be a warning markers in excised…
- Conditions
- Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage IIIA
- Trial name
- NCT01991418
- Where
- China
- Volunteers
- 165 people
- Sponsor
- Hunan Province Tumor Hospital
Kidney Cancer, Lung Cancer
Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer
RATIONALE: Cryotherapy kills tumor cells by freezing them. Giving an injection of GM-CSF before cryotherapy and inhaling GM-CSF after cryotherapy may interfere with the growth of tumor cells and shrink the tumor.
- Conditions
- Kidney Cancer, Lung Cancer, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00514215
- Testing
- sargramostim, flow cytometry, immunoenzyme technique
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Lung Cancer
Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery
RATIONALE: Prognostic testing for early signs of metastases may help doctors detect metastases early and plan more effective treatment.
- Trial name
- NCT00003901
- Testing
- immunohistochemistry staining method, biopsy, surgery
- Where
- 58 sites in United States, Canada
- Volunteers
- 1,310 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Lung Cancer
Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer
RATIONALE: Vaccines may make the body build an immune response to tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood.
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer
- Trial name
- NCT00005023
- Testing
- HER-2/neu peptide vaccine, sargramostim
- Where
- United States
- Sponsor
- University of Washington
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Chemotherapy, Tirapazamine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00033410
- Testing
- carboplatin, paclitaxel, tirapazamine
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- California Cancer Consortium
Stage I Non-Small Cell Lung Cancer AJCC v7, Stage IA Non-Small Cell Lung Carcinoma AJCC v7
Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer
This pilot clinical trial studies the effects of stereotactic body radiation therapy followed by surgery in treating patients with stage I-IIIA non-small cell lung cancer.
- Conditions
- Stage I Non-Small Cell Lung Cancer AJCC v7, Stage IA Non-Small Cell Lung Carcinoma AJCC v7, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT03348748
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Chemotherapeutic Agent Toxicity, Fatigue
First-Line Chemotherapy With or Without Neuromuscular Electrical Stimulation in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Chemotherapeutic Agent Toxicity, Fatigue, Lung Cancer, Musculoskeletal Complications
- Trial name
- NCT01097317
- Testing
- carboplatin, vinorelbine tartrate, neuromuscular electrical stimulation
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- Wales Cancer Trials Unit
Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer
Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy
This research trial studies biomarkers in predicting treatment response in samples from patients with early-stage non-small cell lung cancer previously treated with adjuvant chemotherapy.
- Conditions
- Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer
- Trial name
- NCT01595074
- Testing
- medical chart review, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 950 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Colorectal Cancer
Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer
RATIONALE: Identification of genes that may be associated with developing certain types of cancer may someday provide important information about a person's risk of getting cancer.
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00003329
- Testing
- gene mapping
- Where
- 32 sites in United States
- Volunteers
- 4,000 people
- Sponsor
- Eastern Cooperative Oncology Group
Lung Cancer
EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Knowing the level of oxygen in tumor tissue may help predict the effectiveness of anticancer therapy. EF5 is a drug used in the measurement of oxygen in tumor tissue.
- Trial name
- NCT00041028
- Testing
- EF5, flow cytometry, immunohistochemistry staining method
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Non-Squamous Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
This phase II trial studies how well Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in treating patients with stage I-IIIA non-small cell lung cancer that can be removed by surgery.
- Conditions
- Non-Squamous Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
- Trial name
- NCT03366766
- Testing
- Nivolumab, Cisplatin, Pemetrexed Disodium
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Lung Carcinoma, Lung Non-Small Cell Carcinoma
Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
This phase II trial tests the effectiveness and safety of artificial intelligence (AI) to determine dose recommendation during stereotactic body radiation therapy (SBRT) planning in patients with primary lung cancer or tumors…
- Conditions
- Lung Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Lung, Stage I Lung Cancer AJCC v8
- Trial name
- NCT05802186
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Northwestern University
Lung Cancer, Lymphoma
Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: Vandetanib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways.
- Conditions
- Lung Cancer, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer
- Trial name
- NCT00734890
- Testing
- bevacizumab, vandetanib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Febrile Neutropenia, Stage 0 Breast Cancer
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
This randomized clinical trial studies prophylactic colony stimulating factor management in patients with breast, colorectal or non-small cell lung cancer receiving chemotherapy and with risk of developing febrile neutropenia.
- Conditions
- Febrile Neutropenia, Stage 0 Breast Cancer, Stage 0 Colorectal Cancer, Stage 0 Non-Small Cell Lung Cancer
- Trial name
- TrACER (NCT02728596)
- Testing
- Preventive Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 160 sites in United States, Puerto Rico
- Volunteers
- 3,665 people
- Sponsor
- SWOG Cancer Research Network
Non Small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation
To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
This is a phase II, prospective, multi-centre study. To assess the efficacy and safety of furmonertinib in patients with epidermal growth factor receptor 20ins mutation positive stage IB-IIIA Non-small Cell Lung Carcinoma…
- Trial name
- NCT06192849
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Juan LI, MD